Full Breakdown
US Military Launches MDMA-Assisted Therapy Trials for Service Members with PTSD
5/1/2026, 3:42:49 PM
New MDMA Trials Target PTSD in Service Members
The Department of Defense has approved two randomized, placebo-controlled trials that will enroll 186 service personnel diagnosed with post-traumatic stress disorder. Participants will receive guided MDMA-assisted therapy sessions, with enrollment slated for later 2026 and dosing expected in 2027.
Historical and Policy Context
During World War II the Army used barbiturates to induce sleep for injured soldiers, later deemed ineffective. In the 1950s the military tested LSD at a classified Maryland site. The 2023 National Defence Authorization Act, signed by President Joe Biden and Rep. Morgan Luttrell, mandated renewed psychedelic research. An executive order signed by President Donald Trump on 18 April cited veteran suicide as a national tragedy.
Study Design and Funding
The DoD granted $4.9 million each to Walter Reed National Military Medical Center and Emory University. At Walter Reed, 91 service members will receive three MDMA doses over ten months and will not be deployed. The Emory site will enroll a comparable cohort, for a total of 186 participants. DoD and VA therapists begin training next week. MAPS has trained 250 U.S. therapists and 55 in Ukraine.
Official Statements & Responses
Deputy Under Secretary Sean O’Keefe said the DoD is closely monitoring the trials. The National Defence Authorization Act frames the research as a tool to “heal and stay in the fight.” Rep. Morgan Luttrell stressed that service members deserve every available tool. President Trump called veteran suicide “a national tragedy” and linked the executive order to prevention.
Criticism & Opposition
Ethnobotanist Dennis McKenna warned that restoring soldiers through psychedelics to redeploy them would be “cynical and cruel.” Rick Doblin said participants may relapse if they return to stressful combat. Critics argue MDMA therapy could blunt moral injury or be used to enhance combat readiness, raising ethical concerns about weaponizing mental-health treatment.
Conflicting Reports & Gaps
The protocols prohibit deployment during treatment, but the length of post-trial service restrictions is not defined. Enrollment numbers for the Emory cohort have not been disclosed. MDMA-assisted therapy remains unapproved in Ukraine, though Ukrainian troops have accessed ketamine for PTSD.
Verbatim Quotes
“Helping people process trauma, whoever they are, is probably better than not,” — Rick Doblin, MAPS Founder
“Our men and women in uniform deserve every tool available to heal and stay in the fight,” — Morgan Luttrell, Veteran Navy SEAL
“It would be completely cynical and cruel of the government to throw them back into combat,” — Dennis McKenna, Ethnobotanist
“The suicide epidemic among veterans is a national tragedy,” — Donald Trump, Former President
What’s Next
Volunteer recruitment begins in late 2026, with the first MDMA doses slated for 2027. Positive results could lead to broader DoD adoption of psychedelic-assisted therapy for PTSD. Trials in Israel and ongoing therapist training in Ukraine indicate expanding international interest.
